Trial intelligence / Profile preview

MSCs and CAR-T Cells in Autoimmune Diseases

NCT06435897Phase 2Not yet recruiting

Sponsor
Shenzhen Geno-Immune Medical Institute
Start
Jun 2027
Primary completion
Dec 2028
Modality
Gene Editing, Gene Silencing, CAR-T Cells
Countries
1
01

Overview

A Phase 2 trial of 4SCAR19 in autoimmune diseases, sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Jun 2027; status: not yet recruiting.

02

Drugs

4SCAR19
03

Conditions

autoimmune diseases

Beyond the preview

Go deeper on NCT06435897.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06435897.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call